Biogen Says Its Back and Ready for ‘Highly Active’ Dealmaking

April 24, 2017 | Biogen Inc. is ready to make some deals. "We're moving, and we're back in terms of augmenting the pipeline," research and development head Michael Ehlers said Friday in an interview. An agreement last week to pay Bristol-Myers Squibb Co. $300 million upfront for an experimental Alzheimer's drug is "hopefully just the beginning of a set of very rigorous but highly active deals." Bloomberg